RTW Investments LP Grows Stake in Replimune Group, Inc. (NASDAQ:REPL)

RTW Investments LP boosted its position in Replimune Group, Inc. (NASDAQ:REPL) by 82.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,065,010 shares of the company’s stock after purchasing an additional 931,223 shares during the period. RTW Investments LP owned about 3.02% of Replimune Group worth $25,007,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its stake in Replimune Group by 42.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 778,163 shares of the company’s stock valued at $9,425,000 after purchasing an additional 232,822 shares in the last quarter. Victory Capital Management Inc. purchased a new position in Replimune Group in the 4th quarter valued at approximately $543,000. Swiss National Bank increased its stake in Replimune Group by 57.4% in the 4th quarter. Swiss National Bank now owns 103,700 shares of the company’s stock valued at $1,256,000 after purchasing an additional 37,800 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Replimune Group by 696.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock valued at $82,000 after purchasing an additional 5,922 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in Replimune Group by 7.3% during the fourth quarter. Bank of New York Mellon Corp now owns 174,518 shares of the company’s stock worth $2,113,000 after buying an additional 11,893 shares in the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Price Performance

REPL stock opened at $7.23 on Friday. Replimune Group, Inc. has a 52-week low of $4.92 and a 52-week high of $17.00. The stock’s fifty day simple moving average is $9.02 and its 200-day simple moving average is $11.36. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $556.82 million, a price-to-earnings ratio of -2.36 and a beta of 0.68.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Equities research analysts expect that Replimune Group, Inc. will post -2.97 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on REPL. JPMorgan Chase & Co. raised their price target on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. BMO Capital Markets raised their price target on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright raised their price target on Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $19.43.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.